Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) is expected to announce its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.

Tevogen Bio Stock Down 2.9%

Shares of TVGN stock opened at $0.27 on Tuesday. The business has a fifty day simple moving average of $0.33 and a 200 day simple moving average of $0.56. The company has a market cap of $54.16 million, a P/E ratio of -1.43 and a beta of -0.80. Tevogen Bio has a twelve month low of $0.23 and a twelve month high of $1.51.

Analysts Set New Price Targets

TVGN has been the subject of a number of research reports. D. Boral Capital dropped their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, November 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG raised its holdings in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after acquiring an additional 152,572 shares during the period. Finally, Bridgeway Capital Management LLC increased its position in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after acquiring an additional 33,000 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.